Ekf Diagnostics Holdings Plc · LSE:EKF
Ekf Diagnostics — Investor Presentation (June 2021)
15 slides from Ekf Diagnostics's investor presentation, Jun 7, 2021
Slide 1: 2021 – 2024 Growth Strategy
EKF Diagnostics Holdings plc 2021 – 2024 Growth Strategy Investor Presentation w/c 7 June 2021
Slide 2: Disclaimer
Disclaimer The information contained in these slides and the accompanying oral presentation (together, the “Presentation”) has been prepared by EKF Diagnostics Holdings plc (the “Company”). The Presentation is subject to updating, completion, revision and amendment without notice and as such it may
Slide 3: Agenda
Agenda Slide no. Introduction 4 Growth plan: 5 1. Life Sciences 6 2. Contract manufacturing 8 3. Acquisitions 9 4. Point of Care 10 5. Mount Sinai Innovation Partners 13 6. Dividend policy 14 3
Slide 4: EKF Diagnostics 2021
EKF Diagnostics 2021 Investment into the business Leverage internal expansion opportunities Significant revenue and EBITDA growth by 31 December 2024 4
Slide 5: Growth plan 2021 - 2024
Growth plan 2021 - 2024 Invest in fueling growth 1. Investment in existing core business (enzymes and contract manufacturing) to drive aggressive organic growth 2. Exploit newly expanded capabilities to meet the demand for contract manufacturing services 3. Seek out complementary, earnings-enhancing
Slide 6: 1. Investment in existing core business to drive aggressive organic growth
1. Investment in existing core business (enzymes and contract manufacturing) to drive aggressive organic growth Life Sciences Increase fermentation capacity through installation of 3,000 and 14,700 litre fermenters in South Bend facility Investment objective is to increase capacity to take on larger
Slide 7: Conservative potential revenue from increased fermentation capacity
Conservative potential revenue from increased fermentation capacity Assumptions: 1,500 L and 3,000 L fermenters on line Q3 2022 14,700 L fermenter on line Q1 2023 12 Sale price assumptions: 14,700 litre fermentation @ $250k - $600k 10 3,000 litre fermentation @ $150k to $250k 1,500 litre fermentatio
Slide 8: 2. Exploit newly expanded capabilities for contract manufacturing services
2. Exploit newly expanded capabilities to meet the demand for contract manufacturing services Leverage relationship with private sector partner to support their diagnostics strategy EKF currently makes kits for their COVID sample collection product in USA, UK and Germany Customer is the largest dist
Slide 9: 3. Seek complementary earnings-enhancing acquisitions
3. Seek complementary earnings-enhancing acquisitions with key strategic value to the core business Three growth areas identified CLIA lab for diagnostic tests – Further area of partnership with global private sector partner – Potential to link to Trellus, Renalytix and Verici – Move into $4bn US di
Slide 10: 4a. Point of Care: brand extensions and new product development (EKF Response)
4. Investment into Point of Care business to maximise distribution network and diversify existing product portfolio 4a. Brand extensions and new product development Launch EKF Response aimed at sepsis testing in critical care settings Multi-parameter device based on next generation Lactate Scout sen
Slide 11: 4a. Point of Care: DiaSpect Tm Mk II, EKF Link, Quo-Test A1c Mk II
4. Investment into Point of Care business to maximise distribution network and diversify existing product portfolio 4a. Brand extensions and new product development Launch DiaSpect Tm Mk II • New functions including memory and LIS (laboratory information system) connectivity • Launch Q4 2021 Introdu
Slide 12: 4b. Maximise the value of existing distribution network
4. Investment into Point of Care business to maximise distribution network and diversify existing product portfolio 4b. Maximise the value of existing distribution network Cardinal Health: Diabetes strategy (b-HB, WB meter, Glycated Albumin) Fisher: Private label b-HB Ortho Clinical: Continue privat
Slide 13: 5. Value from agreement with Mount Sinai Innovation Partners
5. Continue to create additional value for EKF shareholders from our agreement with Mount Sinai Innovation Partners Considerable value already delivered through RenalytixAI, Verici Dx and Trellus Health Relationship will be led by Julian Baines as Non-Executive Deputy Chairman Continue to be in conv
Slide 14: 6. Continue a progressive dividend policy
6. Continue a progressive dividend policy and generate enhanced shareholder returns First ever dividend of 1p per ordinary share paid 1 December 2020 Intention to pay a second dividend of 1.1p on 1 December 2021 Plan to follow progressive dividend policy and continue to provide enhanced returns by d
Slide 15: Thanks
Thanks for your attention
EKF Diagnostics Holdings — Investor Presentation (June 2021) on 6ix